Publications in collaboration with researchers from Instituto de Investigación Biomédica de Salamanca (29)

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

  2. T-reg transcriptomic signatures identify response to check-point inhibitors

    Scientific Reports, Vol. 14, Núm. 1

2023

  1. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. Antitumoral Activity of a CDK9 PROTAC Compound in HER2-Positive Breast Cancer

    International Journal of Molecular Sciences, Vol. 23, Núm. 10

  2. Enhanced Antitumoral Activity of Encapsulated BET Inhibitors When Combined with PARP Inhibitors for the Treatment of Triple-Negative Breast and Ovarian Cancers

    Cancers, Vol. 14, Núm. 18

  3. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  2. Genomic correlates of dna damage in breast cancer subtypes

    Cancers, Vol. 13, Núm. 9

  3. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia

    Biomedicine and Pharmacotherapy, Vol. 144

  4. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  5. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms

    Cancer Letters, Vol. 470, pp. 161-169

  2. An overview of antibody conjugated polymeric nanoparticles for breast cancer therapy

    Pharmaceutics, Vol. 12, Núm. 9, pp. 1-20

  3. Antibody conjugation of nanoparticles as therapeutics for breast cancer treatment

    International Journal of Molecular Sciences, Vol. 21, Núm. 17, pp. 1-21

  4. Checkpoint kinase 1 pharmacological inhibition synergizes with dna-damaging agents and overcomes platinum resistance in basal-like breast cancer

    International Journal of Molecular Sciences, Vol. 21, Núm. 23, pp. 1-14

  5. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

    Breast Cancer Research, Vol. 22, Núm. 1

  6. Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer

    Cancer Letters, Vol. 491, pp. 50-59

  7. Pharmacological screening and transcriptomic functional analyses identify a synergistic interaction between dasatinib and olaparib in triple-negative breast cancer

    Journal of Cellular and Molecular Medicine, Vol. 24, Núm. 5, pp. 3117-3127

  8. Proteolysis targeting chimeras (PROTACs) in cancer therapy

    Journal of Experimental and Clinical Cancer Research, Vol. 39, Núm. 1

  9. Trastuzumab Emtansine: Mechanisms of Action and Resistance, Clinical Progress, and Beyond

    Trends in Cancer, Vol. 6, Núm. 2, pp. 130-146